Genocea Biosciences Performance
| GNCADelisted Stock | USD 0.0002 0.0001 100.00% |
The company retains a Market Volatility (i.e., Beta) of -34.11, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Genocea Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Genocea Biosciences is expected to outperform it. Genocea Biosciences right now retains a risk of 0.0%. Please check out Genocea Biosciences jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to decide if Genocea Biosciences will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Genocea Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong fundamental indicators, Genocea Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 80.4 M | |
| Total Cashflows From Investing Activities | -3.2 M |
Genocea |
Genocea Biosciences Relative Risk vs. Return Landscape
If you would invest 0.02 in Genocea Biosciences on August 30, 2024 and sell it today you would earn a total of 0.00 from holding Genocea Biosciences or generate 0.0% return on investment over 90 days. Genocea Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Genocea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genocea Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genocea Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genocea Biosciences, and traders can use it to determine the average amount a Genocea Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GNCA |
Based on monthly moving average Genocea Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genocea Biosciences by adding Genocea Biosciences to a well-diversified portfolio.
Genocea Biosciences Fundamentals Growth
Genocea Stock prices reflect investors' perceptions of the future prospects and financial health of Genocea Biosciences, and Genocea Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genocea Stock performance.
| Return On Equity | -5.26 | |||
| Return On Asset | -0.58 | |||
| Operating Margin | (29.59) % | |||
| Current Valuation | (4.53 M) | |||
| Shares Outstanding | 58.78 M | |||
| Price To Earning | (0.59) X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.12 X | |||
| Revenue | 1.64 M | |||
| EBITDA | (34.32 M) | |||
| Cash And Equivalents | 20.14 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 8.79 M | |||
| Debt To Equity | 1.25 % | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (45.37 M) | |||
| Earnings Per Share | (0.53) X | |||
| Total Asset | 55.97 M | |||
| Retained Earnings | (339.66 M) | |||
| Current Asset | 76.41 M | |||
| Current Liabilities | 7.09 M | |||
About Genocea Biosciences Performance
By analyzing Genocea Biosciences' fundamental ratios, stakeholders can gain valuable insights into Genocea Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genocea Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genocea Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Genocea Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 74 people.Things to note about Genocea Biosciences performance evaluation
Checking the ongoing alerts about Genocea Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genocea Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genocea Biosciences is not yet fully synchronised with the market data | |
| Genocea Biosciences has some characteristics of a very speculative penny stock | |
| Genocea Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.64 M. Net Loss for the year was (33.2 M) with profit before overhead, payroll, taxes, and interest of 1.64 M. | |
| Genocea Biosciences currently holds about 20.14 M in cash with (45.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from zacks.com: Why Emcor Group is a Top Momentum Stock for the Long-Term |
- Analyzing Genocea Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genocea Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Genocea Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genocea Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genocea Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genocea Biosciences' stock. These opinions can provide insight into Genocea Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Genocea Stock
If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |